MYNZ
NASDAQMainz Biomed N.V.
Website
News25/Ratings4
News · 26 weeks36-100%
2025-11-022026-04-26
Mix1690d
- Insider7(44%)
- SEC Filings5(31%)
- Other3(19%)
- Leadership1(6%)
Latest news
25 items- SECSEC Form PRE 14A filed by Mainz Biomed N.V.PRE 14A - MAINZ BIOMED N.V. (0001874252) (Filer)
- SECMainz Biomed N.V. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - MAINZ BIOMED N.V. (0001874252) (Filer)
- PRMainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of DirectorsBERKELEY, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced that Robert P. Liscouski has been appointed Chairman of its Board of Directors. Further, the Company announced that it plans to change its name to Quantum Cyber and change its Nasdaq ticker symbol to QUCY, beginning on March 12, 2026. The permanent election of Mr. Liscouski and the change of Company name will become effective at the Company's extraordinary general meeting, being planned for April 2026. The Company will begin doing business as Quantum Cyber and trading under the symbol QUCY beginning on M
- INSIDERSEC Form 4 filed by Director Lazar David E.4 - MAINZ BIOMED N.V. (0001874252) (Issuer)
- INSIDERNew insider Lazar David E. claimed no ownership of stock in the company (SEC Form 3)3 - MAINZ BIOMED N.V. (0001874252) (Issuer)
- PRMainz Biomed to Present at the Pancreatic Cancer Session at Digestive Disease Week, Demonstrating Effectiveness of mRNA Biomarkers in Blood SamplesBERKELEY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, is excited to announce its participation in the renowned Digestive Disease Week (DDW) 2026 in Chicago, Illinois. At the conference the Company will present its poster titled "BLOOD-BASED MRNA SIGNATURE FOR DETECTION OF PANCREATIC DUCTAL ADENOCARCINOMA AND DISCRIMINATION OF INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS". "We are thrilled about the team's progress in confirming the strong clinical results from our discovery study. What's particularly exciting is that our algorithm and biomarker selection can identify neoplasms
- INSIDERChief Financial Officer Caragol William J was granted 290,000 units of Ordinary Shares, increasing direct ownership by 372% to 367,899 units (SEC Form 4)4 - MAINZ BIOMED N.V. (0001874252) (Issuer)
- INSIDERDirector Dreismann Heinrich was granted 45,000 units of Ordinary Shares, increasing direct ownership by 228% to 64,700 units (SEC Form 4)4 - MAINZ BIOMED N.V. (0001874252) (Issuer)
- INSIDERDirector Tibbitts Gregory J was granted 45,000 units of Ordinary Shares, increasing direct ownership by 414% to 55,875 units (SEC Form 4)4 - MAINZ BIOMED N.V. (0001874252) (Issuer)
- INSIDERChief Executive Officer Baechler Guido was granted 440,000 units of Ordinary Shares, increasing direct ownership by 267% to 605,058 units (SEC Form 4)4 - MAINZ BIOMED N.V. (0001874252) (Issuer)
- INSIDERNew insider Hekland Hans claimed ownership of 45,000 units of Ordinary Shares (SEC Form 3)3 - MAINZ BIOMED N.V. (0001874252) (Issuer)
- SECSEC Form S-8 filed by Mainz Biomed N.V.S-8 - MAINZ BIOMED N.V. (0001874252) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Mainz Biomed N.V.SCHEDULE 13G/A - MAINZ BIOMED N.V. (0001874252) (Subject)
- SECMainz Biomed N.V. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits8-K - MAINZ BIOMED N.V. (0001874252) (Filer)
- PRMainz Biomed Announces 6.0 USD Million Private Placement and Strategic UpdateBERKELEY, Calif. and MAINZ, Germany, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, announced a series of strategic transactions designed to strengthen its liquidity position, transition the business to a focus on its pancreatic cancer detection program in the U.S., and provide flexibility as the Company continues its operations while evaluating growth opportunities and broader strategic alternatives. On February 13, 2026, Mainz Biomed N.V. (the "Company") entered into a securities purchase agreement for a 6.0 USD million private placement with investor David Lazar. The financing w
- SECMainz Biomed N.V. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - MAINZ BIOMED N.V. (0001874252) (Filer)
- INSIDERNew insider Caragol William J claimed no ownership of stock in the company (SEC Form 3)3 - MAINZ BIOMED N.V. (0001874252) (Issuer)
- INSIDERNew insider Dreismann Heinrich claimed no ownership of stock in the company (SEC Form 3)3 - MAINZ BIOMED N.V. (0001874252) (Issuer)
- INSIDERNew insider Tibbitts Gregory J claimed no ownership of stock in the company (SEC Form 3)3 - MAINZ BIOMED N.V. (0001874252) (Issuer)
- INSIDERNew insider Baechler Guido claimed ownership of 6,362 units of Ordinary Shares (SEC Form 3)3 - MAINZ BIOMED N.V. (0001874252) (Issuer)
- INSIDERAmendment: Large owner Donahue Kevin Michael bought $1,034,350 worth of shares (685,000 units at $1.51) (SEC Form 4)4/A - MAINZ BIOMED N.V. (0001874252) (Issuer)
- INSIDERAmendment: New insider Donahue Kevin Michael claimed ownership of 685,000 shares (SEC Form 3)3/A - MAINZ BIOMED N.V. (0001874252) (Issuer)
- INSIDERLarge owner Donahue Kevin Michael bought $258,827,700,000 worth of shares (643,850 units at $402,000.00) (SEC Form 4)4 - MAINZ BIOMED N.V. (0001874252) (Issuer)
- INSIDERNew insider Donahue Kevin Michael claimed ownership of 643,850 shares (SEC Form 3)3 - MAINZ BIOMED N.V. (0001874252) (Issuer)
- PRMainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual MeetingBERKELEY, Calif. and , Jan. 14, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, is excited to announce its participation in the upcoming American Association for Cancer Research (AACR) 2026 Annual Meeting. This prestigious conference will be held April 17 to 22, 2026, in San Diego, California. Organized by the American Association for Cancer Research, this premier event gathers scientists, clinicians, and industry leaders from around the world to share groundbreaking cancer research and explore new approaches in oncology. At AACR the Company will present the results of its verification study e
MYNZ FAQ
7 questionsWhat does Mainz Biomed N.V. do?
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic tests for clinical diagnostics in the area of human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, an early-stage molecular lateral-flow test; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.Where does MYNZ stock trade?
Mainz Biomed N.V. (MYNZ) is listed on NASDAQ.What sector and industry is MYNZ in?
Mainz Biomed N.V. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Mainz Biomed N.V. go public?
Mainz Biomed N.V. (MYNZ) completed its IPO in 2021.What are analysts saying about MYNZ?
Mainz Biomed N.V. has had 4 recent analyst actions on file. The most recent action was from Maxim Group: Buy with a $1400.00 price target on 2025-02-14. Recent price targets range from $1400.00 to $2500.00.What companies are similar to MYNZ?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), NVS (Novartis AG). Compare MYNZ side-by-side with any of them on Quantisnow.How can I track MYNZ on Quantisnow?
Quantisnow aggregates Mainz Biomed N.V.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MYNZ to receive live email and push alerts on every new disclosure.